REN and metabolic syndrome: The prevalence of dyslipidemia was higher in low PLR group (41.7% vs. 20.0%, P = 0.048), whereas the percentage of renin-angiotensin system (RAS) blocker usage was lower in low PLR group (19.4% vs. 45.7%, P = 0.018).